SCHEMBL23926951

SCHEMBL23926951

COc1cc(Oc2ccc(Nc3ccccc3N)cn2)ccc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 3/20 0.49
GAA P10253 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
THRB P10828 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
MMP14 P50281 1/20 0.49
RAB9A P51151 1/20 0.49
PIK3CD O00329 2/20 0.47
PIK3CA P42336 2/20 0.47
PIK3CB P42338 2/20 0.47
PIK3CG P48736 2/20 0.47
MAPK14 Q16539 8/20 0.42
MAPK13 O15264 2/20 0.42
MAPK12 P53778 2/20 0.42
MAPK11 Q15759 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079564 1.00 MAPT (0.49) MAPTALDH1A1KDM4EGAATDP1
SCHEMBL23927014 0.89 PIK3CD (0.47) MAPTALDH1A1KDM4EGAATDP1
SCHEMBL30079766 0.89 PIK3CD (0.47) MAPTALDH1A1KDM4EGAATDP1
SCHEMBL23926961 0.82 L3MBTL1 (0.48) MAPTALDH1A1GAATDP1MEN1
SCHEMBL30079634 0.82 L3MBTL1 (0.48) MAPTALDH1A1GAATDP1MEN1
SCHEMBL23927082 0.81 PIK3CA (0.46) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL30079725 0.81 PIK3CA (0.46) ALDH1A1KDM4ETDP1MEN1KMT2A
SCHEMBL30079796 0.80 PIK3CA (0.48) ALDH1A1KDM4EMEN1KMT2APIK3CD
SCHEMBL23926990 0.80 PIK3CA (0.48) ALDH1A1KDM4EMEN1KMT2APIK3CD
SCHEMBL4938262 0.79 PIK3CA (0.60) MAPTALDH1A1KDM4EGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 MAPT 1023/4885ALDH1A1 2760/4885KDM4E 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.